It was reported on July 24 that Sanofi (NASDAQ:SNY) shares underperformed in European trading following the company’s decision to drop the clinical development of its eczema candidate, amlitelimab, for moderate-to-severe atopic dermatitis. Rather than a fundamental breakdown, the move reflects an aggressive R&D pipeline review under CEO Belén Garijo, who chose to pull the plug after efficacy and safety data failed to support global regulatory submissions.
For a mega-cap pharmaceutical giant like Sanofi, valued at more than $100 billion, abandoning a zero-revenue clinical trial asset is a necessary cost of doing business. The market’s knee-jerk reaction compounded recent sell-side caution, including a July 8 research note from Morgan Stanley analyst Sarita Kapila, who trimmed her price target to $49 from $52 with an Equal Weight rating.
Yet, for long-term investors, the pivot brings a crucial dynamic into focus: Scrapping non-performing clinical assets isn’t a sign of operational weakness; it’s a disciplined strategic move to eliminate cash burn and reallocate capital toward higher-yielding growth engines.
BULL CASE
The bullish thesis hinges on management’s willingness to cut dead weight and protect operating margins. Amlitelimab generated no commercial revenue, as Sanofi discontinued its development in atopic dermatitis after concluding it did not provide a meaningful advantage over existing standards of care. Eliminating further trial expenditures frees up significant cash reserves, allowing management to double down on cutting-edge, high-margin platforms, such as bispecific antibodies and advanced vaccines, that offer a much higher probability of replacing aging blockbusters.
Furthermore, Sanofi’s core operational engine remains exceptionally robust. The company’s crown jewel, Dupixent, continues to deliver strong double-digit growth across multiple type-2 inflammatory indications, generating massive cash flows to fund organic R&D and targeted bolt-on M&A. Outside of dermatology, Sanofi continues to score high-profile wins, including the July 9 U.S. FDA approval of Sarclisa Escena, the first anticancer therapy for multiple myeloma delivered via an on-body injector. Additionally, Morgan Stanley analyst Sarita Kapila noted in her July 8 research report that Sanofi is set for a solid Q2, with lower R&D expenses expected to drive earnings-per-share (EPS) upside.
BEAR CASE
Bears argue that dropping amlitelimab weakens Sanofi’s long-term market presence in dermatology. Amlitelimab, acquired through the $1.1 billion buyout of Kymab, was originally viewed as a potential successor candidate to extend Sanofi’s dominance in inflammatory disease once Dupixent faces eventual patent expirations in the 2030s. Scrapping the candidate represents an unrecoverable write-down on the Kymab acquisition.
Sell-side sentiment reflects this ongoing uncertainty. Morgan Stanley’s decision to maintain a neutral Equal Weight rating highlights market skepticism surrounding Sanofi’s mid-stage pipeline visibility. Skeptics maintain that until the company demonstrates a clear successor pipeline to Dupixent, the stock’s valuation multiple may remain constrained relative to its large-cap pharmaceutical peers.
INSIDER MONKEY HEDGE FUND DATA ANALYSIS
According to Insider Monkey’s database of Q2 2026 hedge fund filings, institutional sentiment toward Sanofi (NASDAQ:SNY) remained stable, with 32 hedge funds holding positions at the end of the quarter, unchanged from Q1 2026. The largest institutional holder was Levin Easterly Partners, led by John Murphy, which owned 235,126 shares valued at approximately $10.03 million. During the quarter, the firm increased its stake by 23%, bringing the position to 0.51% of its overall equity portfolio. The unchanged number of hedge fund holders suggests that while institutional investors are not turning more bullish on the stock, they also are not exiting their positions, reflecting a cautious but steady level of confidence as Sanofi continues to realign its pipeline.
WHAT INVESTORS SHOULD WATCH NEXT
Investors should tune into Sanofi’s upcoming Q2 2026 earnings report on July 30 for management’s updated financial guidance and pipeline updates under CEO Belén Garijo. Key metrics to track include whether reduced R&D spending generates the anticipated EPS beat highlighted by Morgan Stanley, volume growth trajectories for Dupixent, and fresh clinical readouts across the company’s early-to-mid stage bispecific antibody pipeline.
While we acknowledge the risk and potential of SNY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SNY and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center